Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related non-alcoholic fatty liver disease - Ma, Y; Zhang, G; Kuang, Z (Front Pharmacol, 2022)